Excelsyn, a pharmaceutical and biotech services firm, has received a seven figure investment from two private equity firms. The company plans to continue the growth of its business in the UK and internationally after securing the backing of Endless and NorthStar Equity Investors.

Excelsyn, a pharmaceutical and biotech services firm, has received a seven figure investment from two private equity firms. The company plans to continue the growth of its business in the UK and internationally after securing the backing of Endless and NorthStar Equity Investors.

Newcastle-based Excelsyn, which provides advanced manufacturing, process technology and consultancy services to the pharmaceutical and biotech industries, will use the undisclosed funding to improve its services by investing in its operations and developing its intellectual property.

Endless’ investment was managed by Aidan Robson, who says the firm has backed the company due to its growth record and the strength of its management. He adds that this is the firm’s first deal in the northeast, a region it is looking to expand into.

Excelsyn, which was established in 2003 by chairman and chief executive Ian Shott, expects to report turnover of £13 million in the year to May 2007.